BioSpace

Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival

Bayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.

By BioSpace

1 min read
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights